Triple Combination Therapy in High Risk Crohn's Disease (CD)

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

September 22, 2020

Study Completion Date

July 5, 2022

Conditions
Crohn Disease
Interventions
DRUG

Vedolizumab

Vedolizumab intravenous infusion.

DRUG

Adalimumab

Adalimumab injection for subcutaneous use.

DRUG

Methotrexate

Methotrexate oral tablets.

Trial Locations (32)

10029

Icahn School of Medicine at Mt. Sinai, New York

28204

Carolinas HealthCare System Digestive Health, Charlotte

28801

Digestive Health Partners, PS, Asheville

33761

Gastro Florida, Clearwater

36305

Digestive Health Specialists of the Southeast, Dothan

39216

University of Mississippi Medical Center, Jackson

43210

The Ohio State University Wexner Medical Center, Columbus

48098

Center for Digestive Health, Troy

48197

Huron Gastroenterology Associates, Ypsilanti

55446

Minnesota Gastroenterology, PA - Plymouth, Plymouth

60201

Northshore University HealthSystem, Evanston

66160

University of Kansas Medical Center, Kansas City

66606

Cotton O'Neil Clinical Research, Topeka

70809

Texas Digestive Disease Consultants Baton Rouge, Baton Rouge

71105

Louisana Research Center, LLC, Shreveport

73112

Digestive Disease Specialists, Inc., Oklahoma City

74104

Options Health Research, LLC, Tulsa

75701

Tyler Research Institute, LLC, Tyler

76092

Texas Digestive Disease Consultants Southlake, Southlake

77030

Baylor College of Medicine, Houston

77598

Texas Digestive Disease Consultants, Webster, Webster

78229

Pinnacle Clinical Research, San Antonio

83404

Grand Teton Research Group, PLLC, Idaho Falls

84132

University of Utah Health Sciences Center, Salt Lake City

89113

Las Vegas Medical Research, Las Vegas

98405

Digestive Health Specialists, Tacoma

30342-5000

Atlanta Gastroenterology Associates, Atlanta

T6L 6K3

Covenant Health, Edmonton

V8V 3M9

PerCuro Clinical Research Ltd, Victoria

N6A 5W9

LHSC - Victoria Hospital, London

L4L 4Y7

Toronto Digestive Disease Associates Inc, Vaughan

J1G 2E8

CIUSSS de I'Estrie-CHUS, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02764762 - Triple Combination Therapy in High Risk Crohn's Disease (CD) | Biotech Hunter | Biotech Hunter